Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease.
Chan, Webber; Lynch, Nicole; Bampton, Peter; Chang, Jeff; Chung, Alvin; Florin, Timothy; Hetzel, David J; Jakobovits, Simon; Moore, Gregory; Pavli, Paul; Radford-Smith, Graham; Thin, Lena; Baraty, Brandon; Haifer, Craig; Yau, Yunki; Leong, Rupert W L.
Eur J Gastroenterol Hepatol
; 30(7): 735-740, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29727386
Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease.
Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease.
Disease-specific alterations in the enteric virome in inflammatory bowel disease.
Inflammatory bowel disease as a model for translating the microbiome.
Pooled sequencing of 531 genes in inflammatory bowel disease identifies an associated rare variant in BTNL2 and implicates other immune related genes.
Environmental risk factors for inflammatory bowel diseases: a review.
Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy.
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia.
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease.